PhaseBio Pharmaceuticals Inc
NASDAQ:PHAS
PhaseBio Pharmaceuticals Inc
Revenue
PhaseBio Pharmaceuticals Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
PhaseBio Pharmaceuticals Inc
NASDAQ:PHAS
|
Revenue
$10.8m
|
CAGR 3-Years
153%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
PhaseBio Pharmaceuticals Inc
Revenue Breakdown
Breakdown by Geography
PhaseBio Pharmaceuticals Inc
Breakdown by Segments
PhaseBio Pharmaceuticals Inc
Total Revenue:
10.8m
USD
|
Sublicense Revenue:
10.8m
USD
|
License:
10.2m
USD
|
Development And Regulatory Services:
608k
USD
|
See Also
What is PhaseBio Pharmaceuticals Inc's Revenue?
Revenue
10.8m
USD
Based on the financial report for Dec 31, 2021, PhaseBio Pharmaceuticals Inc's Revenue amounts to 10.8m USD.
What is PhaseBio Pharmaceuticals Inc's Revenue growth rate?
Revenue CAGR 3Y
153%
Over the last year, the Revenue growth was 3 285%. The average annual Revenue growth rates for PhaseBio Pharmaceuticals Inc have been 153% over the past three years .